<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01215643</url>
  </required_header>
  <id_info>
    <org_study_id>CDEB025A2211</org_study_id>
    <secondary_id>2010-020034-26</secondary_id>
    <nct_id>NCT01215643</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants</brief_title>
  <official_title>A Multicenter, Randomized, Open Label, Parallel-group Phase IIB Study on the Efficacy and Safety of Oral Regimens of DEB025 Alone or in Combination With Ribavirin Versus Standard of Care (Peg-IFNα2a Plus Ribavirin) in Treatment-naïve Hepatitis C Genotype 2 and 3 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Debiopharm International SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Debiopharm International SA</source>
  <brief_summary>
    <textblock>
      The study is to investigate whether alisporivir (ALV; DEB025) alone or in combination with
      either ribavirin (RBV) or peginterferon alfa-2a (PEG) is more efficient compared to standard
      of care (PEG+RBV) in treatment-naïve participants with hepatitis C virus (HCV) genotype 2 and
      3. In addition, triple therapy with DEB025 plus standard of care will be applied to
      participants not achieving rapid viral response (RVR) in the different arms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Rapid Viral Response (RVR) After 4 Weeks of Treatment &lt; the Limit of Quantification (RVR4LOQ)</measure>
    <time_frame>after 4 weeks of treatment</time_frame>
    <description>RVR4LOQ was defined as RVR [serum hepatitis C virus (HCV) ribonucleic acid (RNA) &lt; the limit of quantification (LOQ), i.e., &lt; 25 IU/mL], after 4 weeks of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With RVR After 4 Weeks of Treatment &lt; the Limit of Detection (RVR4LOD)</measure>
    <time_frame>after 4 weeks of treatment</time_frame>
    <description>RVR4LOD was defined as Rapid Viral Response (RVR) [serum HCV RNA &lt; the limit of detection (LOD), i.e., &lt; 10 IU/mL], after 4 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With RVR4LOQ and RVR4LOD (Genotype 2)</measure>
    <time_frame>after 4 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With RVR4LOQ and RVR4LOD (Genotype 3)</measure>
    <time_frame>after 4 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Complete Early Viral Response (cEVR) After 12 Weeks of Treatment (cEVR12LOQ and cEVR12LOD)</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
    <description>cEVR12LOQ and cEVR12LOD were defined as cEVR [serum HCV RNA &lt; LOQ and &lt; LOD] after 12 weeks of treatment, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With cEVR12LOQ and cEVR12LOD (Genotype 2)</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With cEVR12LOQ and cEVR12LOD (Genotype 3)</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With End of Treatment Response (ETR) Within 24 Weeks (ETR24LOQ and ETR24LOD)</measure>
    <time_frame>at end of treatment, within 24 weeks</time_frame>
    <description>ETR24LOQ and ETR24LOD were defined as ETR [serum HCV RNA &lt; LOQ and &lt; LOD] after 24 weeks of treatment or when prematurely discontinued.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ETR24LOQ and ETR24LOD (Genotype 2)</measure>
    <time_frame>at end of treatment, within 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ETR24LOQ and ETR24LOD (Genotype 3)</measure>
    <time_frame>at end of treatment, within 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With RVR Who Achieved Sustained Viral Response (SVR) 12 Weeks After the End of Treatment (SVR12LOQ and SVR12LOD)</measure>
    <time_frame>12 weeks after the end of treatment</time_frame>
    <description>SVR12LOQ and SVR12LOD were defined as Sustained Viral Response (SVR) [serum HCV RNA &lt; LOQ and &lt; LOD] 12 weeks after treatment, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With RVR Who Achieved SVR12LOQ and SVR12LOD (Genotype 2)</measure>
    <time_frame>12 weeks after the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With RVR Who Achieved SVR12LOQ and SVR12LOD (Genotype 3)</measure>
    <time_frame>12 weeks after the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With RVR Who Achieved SVR at 24 Weeks After the End of Treatment (SVR24LOQ and SVR24LOD)</measure>
    <time_frame>24 weeks after the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With RVR Who Achieved SVR24LOQ and SVR24LOD (Genotype 2)</measure>
    <time_frame>24 weeks after the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With RVR Who Achieved SVR24LOQ and SVR24LOD (Genotype 3)</measure>
    <time_frame>24 weeks after the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With On-treatment Viral Breakthrough</measure>
    <time_frame>within 24 weeks of treatment</time_frame>
    <description>Viral breakthrough was defined as either:
Confirmed increase of HCV RNA ≥1 log10 above nadir (nadir = lowest HCV RNA value during treatment), or
HCV RNA becoming ≥ 100 IU/mL after previously being undetectable (&lt; LOD) during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Viral Relapse</measure>
    <time_frame>within 24 weeks after the end of treatment</time_frame>
    <description>Viral relapse was defined as having reappearance of detectable HCV RNA after previously being undetectable (&lt; LOD) during treatment.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">340</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>ALV 1000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alisporivir (ALV) 600 mg twice daily (BID) for 1 week, followed by ALV 1000 mg once daily (QD) during Weeks 2 to 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALV 600 mg+RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alisporivir (ALV) 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with ribavirin (RBV) during Weeks 2 to 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALV 800 mg+RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alisporivir (ALV) 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALV 600 mg+PEG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alisporivir (ALV) 600 mg BID with Peginterferon alfa-2a (PEG) for 1 week, followed by ALV 600 mg QD with PEG once weekly during Weeks 2 to 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG+RBV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peginterferon alfa-2a (PEG) and RBV during Weeks 1 to 24.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alisporivir</intervention_name>
    <description>ALV 200 mg soft gel capsules administered orally</description>
    <arm_group_label>ALV 1000 mg</arm_group_label>
    <arm_group_label>ALV 600 mg+RBV</arm_group_label>
    <arm_group_label>ALV 800 mg+RBV</arm_group_label>
    <arm_group_label>ALV 600 mg+PEG</arm_group_label>
    <other_name>DEB025</other_name>
    <other_name>ALV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <description>PEG 180 μg administered via subcutaneous (s.c.) injection once weekly</description>
    <arm_group_label>ALV 600 mg+PEG</arm_group_label>
    <arm_group_label>PEG+RBV</arm_group_label>
    <other_name>Pegasys®</other_name>
    <other_name>PEG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>RBV 400 mg (2 x 200 mg tablets) administered orally twice daily (BID)</description>
    <arm_group_label>ALV 600 mg+RBV</arm_group_label>
    <arm_group_label>ALV 800 mg+RBV</arm_group_label>
    <arm_group_label>PEG+RBV</arm_group_label>
    <other_name>Copegus®</other_name>
    <other_name>RBV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Chronic hepatitis C viral infection

          -  Plasma HCV RNA level lower limit ≥ 10,000 IU/ml assessed by quantitative polymerase
             chain reaction (qPCR) or equivalent at screening (no upper limit)

          -  HCV genotype 2 or 3

          -  No previous treatment for hepatitis C infection

        Exclusion criteria:

          -  Evidence of cirrhosis at the time of screening

          -  Evidence of hepatocellular carcinoma at the time of screening

          -  Any other cause of relevant liver disease other than HCV

          -  Alanine aminotransferase (ALT) ≥ 10 times upper limit of normal (ULN)

          -  Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp Rees-Stealy Medical Group, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research and Education Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Island View Gastroenterology Associates</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hawai Medical Center East LLC</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cotton O'Neil Clinical Research</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Office of Dr. Claudia Martorell</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The North Texas Research Institute</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Associates of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Specialist of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamo Medical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Center</name>
      <address>
        <city>Greenslopes</city>
        <state>Queensland</state>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1H2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4V 1P7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Clichy Cedex</city>
        <zip>92118</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75006</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10969</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trivandrum</city>
        <state>Kerala</state>
        <zip>695607</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400036</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ludhiana</city>
        <state>Punjab</state>
        <zip>141001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <zip>226014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guwahati</city>
        <zip>781006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haryana</city>
        <zip>122001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyderabad - Andhra Pradesh</city>
        <zip>500012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mumbai</city>
        <zip>400020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Delhi</city>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Inestigative Site</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Inestigative Center</name>
      <address>
        <city>Pusan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pusan</city>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Korea Ltd.</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>738-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-540</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lódz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warsaw</city>
        <zip>01 - 201</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion de Investigacion de Diego</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Niaosong Township</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>ROC112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yun-Lin</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Songkla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glasgow - Scotland</city>
        <zip>G12 OYN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Pawlotsky JM, Flisiak R, Sarin SK, Rasenack J, Piratvisuth T, Chuang WL, Peng CY, Foster GR, Shah S, Wedemeyer H, Hézode C, Zhang W, Wong KA, Li B, Avila C, Naoumov NV; VITAL-1 study team. Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection. Hepatology. 2015 Oct;62(4):1013-23. doi: 10.1002/hep.27960. Epub 2015 Aug 10.</citation>
    <PMID>26118427</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2010</study_first_submitted>
  <study_first_submitted_qc>October 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2010</study_first_posted>
  <results_first_submitted>July 20, 2016</results_first_submitted>
  <results_first_submitted_qc>July 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 30, 2016</results_first_posted>
  <last_update_submitted>July 20, 2016</last_update_submitted>
  <last_update_submitted_qc>July 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic hepatitis C genotype 2</keyword>
  <keyword>Chronic hepatitis C genotype 3</keyword>
  <keyword>Cyclophilin inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ALV 1000 mg</title>
          <description>Alisporivir (ALV) 600 mg twice daily (BID) for 1 week, followed by ALV 1000 mg once daily (QD) during Weeks 2 to 24.</description>
        </group>
        <group group_id="P2">
          <title>ALV 600 mg+RBV</title>
          <description>ALV 600 mg BID with ribavirin (RBV) for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.</description>
        </group>
        <group group_id="P3">
          <title>ALV 800 mg+RBV</title>
          <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.</description>
        </group>
        <group group_id="P4">
          <title>ALV 600 mg+PEG</title>
          <description>ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with peginterferon alfa-2a (PEG) during Weeks 2 to 24.</description>
        </group>
        <group group_id="P5">
          <title>PEG+RBV</title>
          <description>PEG and RBV during Weeks 1 to 24.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="84"/>
                <participants group_id="P3" count="94"/>
                <participants group_id="P4" count="39"/>
                <participants group_id="P5" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="82"/>
                <participants group_id="P4" count="35"/>
                <participants group_id="P5" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>ALV 1000 mg</title>
          <description>ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.</description>
        </group>
        <group group_id="B2">
          <title>ALV 600 mg+RBV</title>
          <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.</description>
        </group>
        <group group_id="B3">
          <title>ALV 800 mg+RBV</title>
          <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.</description>
        </group>
        <group group_id="B4">
          <title>ALV 600 mg+PEG</title>
          <description>ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.</description>
        </group>
        <group group_id="B5">
          <title>PEG+RBV</title>
          <description>PEG and RBV during Weeks 1 to 24.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="83"/>
            <count group_id="B2" value="84"/>
            <count group_id="B3" value="94"/>
            <count group_id="B4" value="39"/>
            <count group_id="B5" value="40"/>
            <count group_id="B6" value="340"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.2" spread="11.27"/>
                    <measurement group_id="B2" value="42.8" spread="11.77"/>
                    <measurement group_id="B3" value="42.6" spread="11.00"/>
                    <measurement group_id="B4" value="43.2" spread="10.56"/>
                    <measurement group_id="B5" value="39.9" spread="11.20"/>
                    <measurement group_id="B6" value="41.8" spread="11.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Rapid Viral Response (RVR) After 4 Weeks of Treatment &lt; the Limit of Quantification (RVR4LOQ)</title>
        <description>RVR4LOQ was defined as RVR [serum hepatitis C virus (HCV) ribonucleic acid (RNA) &lt; the limit of quantification (LOQ), i.e., &lt; 25 IU/mL], after 4 weeks of treatment.</description>
        <time_frame>after 4 weeks of treatment</time_frame>
        <population>Full Analysis Set (FAS), defined as all participants to whom study treatment was correctly assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>ALV 1000 mg</title>
            <description>ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.</description>
          </group>
          <group group_id="O2">
            <title>ALV 600 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O3">
            <title>ALV 800 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O4">
            <title>ALV 600 mg+PEG</title>
            <description>ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.</description>
          </group>
          <group group_id="O5">
            <title>PEG+RBV</title>
            <description>PEG and RBV during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Rapid Viral Response (RVR) After 4 Weeks of Treatment &lt; the Limit of Quantification (RVR4LOQ)</title>
          <description>RVR4LOQ was defined as RVR [serum hepatitis C virus (HCV) ribonucleic acid (RNA) &lt; the limit of quantification (LOQ), i.e., &lt; 25 IU/mL], after 4 weeks of treatment.</description>
          <population>Full Analysis Set (FAS), defined as all participants to whom study treatment was correctly assigned.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4"/>
                    <measurement group_id="O2" value="36.9"/>
                    <measurement group_id="O3" value="41.9"/>
                    <measurement group_id="O4" value="84.6"/>
                    <measurement group_id="O5" value="72.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With RVR After 4 Weeks of Treatment &lt; the Limit of Detection (RVR4LOD)</title>
        <description>RVR4LOD was defined as Rapid Viral Response (RVR) [serum HCV RNA &lt; the limit of detection (LOD), i.e., &lt; 10 IU/mL], after 4 weeks of treatment.</description>
        <time_frame>after 4 weeks of treatment</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>ALV 1000 mg</title>
            <description>ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.</description>
          </group>
          <group group_id="O2">
            <title>ALV 600 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O3">
            <title>ALV 800 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O4">
            <title>ALV 600 mg+PEG</title>
            <description>ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.</description>
          </group>
          <group group_id="O5">
            <title>PEG+RBV</title>
            <description>PEG and RBV during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With RVR After 4 Weeks of Treatment &lt; the Limit of Detection (RVR4LOD)</title>
          <description>RVR4LOD was defined as Rapid Viral Response (RVR) [serum HCV RNA &lt; the limit of detection (LOD), i.e., &lt; 10 IU/mL], after 4 weeks of treatment.</description>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="23.7"/>
                    <measurement group_id="O4" value="69.2"/>
                    <measurement group_id="O5" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With RVR4LOQ and RVR4LOD (Genotype 2)</title>
        <time_frame>after 4 weeks of treatment</time_frame>
        <population>Participants in the Full Analysis Set with genotype 2 HCV infection</population>
        <group_list>
          <group group_id="O1">
            <title>ALV 1000 mg</title>
            <description>ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.</description>
          </group>
          <group group_id="O2">
            <title>ALV 600 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O3">
            <title>ALV 800 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O4">
            <title>ALV 600 mg+PEG</title>
            <description>ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.</description>
          </group>
          <group group_id="O5">
            <title>PEG+RBV</title>
            <description>PEG and RBV during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With RVR4LOQ and RVR4LOD (Genotype 2)</title>
          <population>Participants in the Full Analysis Set with genotype 2 HCV infection</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RVR4LOQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7"/>
                    <measurement group_id="O2" value="23.3"/>
                    <measurement group_id="O3" value="46.2"/>
                    <measurement group_id="O4" value="81.8"/>
                    <measurement group_id="O5" value="76.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RVR4LOD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="26.9"/>
                    <measurement group_id="O4" value="63.6"/>
                    <measurement group_id="O5" value="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With RVR4LOQ and RVR4LOD (Genotype 3)</title>
        <time_frame>after 4 weeks of treatment</time_frame>
        <population>Participants in the Full Analysis Set with genotype 3 HCV infection</population>
        <group_list>
          <group group_id="O1">
            <title>ALV 1000 mg</title>
            <description>ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.</description>
          </group>
          <group group_id="O2">
            <title>ALV 600 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O3">
            <title>ALV 800 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O4">
            <title>ALV 600 mg+PEG</title>
            <description>ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.</description>
          </group>
          <group group_id="O5">
            <title>PEG+RBV</title>
            <description>PEG and RBV during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With RVR4LOQ and RVR4LOD (Genotype 3)</title>
          <population>Participants in the Full Analysis Set with genotype 3 HCV infection</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RVR4LOQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0"/>
                    <measurement group_id="O2" value="44.4"/>
                    <measurement group_id="O3" value="40.3"/>
                    <measurement group_id="O4" value="85.7"/>
                    <measurement group_id="O5" value="70.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RVR4LOD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="22.4"/>
                    <measurement group_id="O4" value="71.4"/>
                    <measurement group_id="O5" value="63.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Complete Early Viral Response (cEVR) After 12 Weeks of Treatment (cEVR12LOQ and cEVR12LOD)</title>
        <description>cEVR12LOQ and cEVR12LOD were defined as cEVR [serum HCV RNA &lt; LOQ and &lt; LOD] after 12 weeks of treatment, respectively.</description>
        <time_frame>after 12 weeks of treatment</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>ALV 1000 mg</title>
            <description>ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.</description>
          </group>
          <group group_id="O2">
            <title>ALV 600 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O3">
            <title>ALV 800 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O4">
            <title>ALV 600 mg+PEG</title>
            <description>ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.</description>
          </group>
          <group group_id="O5">
            <title>PEG+RBV</title>
            <description>PEG and RBV during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Complete Early Viral Response (cEVR) After 12 Weeks of Treatment (cEVR12LOQ and cEVR12LOD)</title>
          <description>cEVR12LOQ and cEVR12LOD were defined as cEVR [serum HCV RNA &lt; LOQ and &lt; LOD] after 12 weeks of treatment, respectively.</description>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>cEVR12LOQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8"/>
                    <measurement group_id="O2" value="95.2"/>
                    <measurement group_id="O3" value="90.3"/>
                    <measurement group_id="O4" value="94.9"/>
                    <measurement group_id="O5" value="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cEVR12LOD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4"/>
                    <measurement group_id="O2" value="86.9"/>
                    <measurement group_id="O3" value="90.3"/>
                    <measurement group_id="O4" value="84.6"/>
                    <measurement group_id="O5" value="82.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With cEVR12LOQ and cEVR12LOD (Genotype 2)</title>
        <time_frame>after 12 weeks of treatment</time_frame>
        <population>Participants in the Full Analysis Set with genotype 2 HCV infection</population>
        <group_list>
          <group group_id="O1">
            <title>ALV 1000 mg</title>
            <description>ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.</description>
          </group>
          <group group_id="O2">
            <title>ALV 600 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O3">
            <title>ALV 800 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O4">
            <title>ALV 600 mg+PEG</title>
            <description>ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.</description>
          </group>
          <group group_id="O5">
            <title>PEG+RBV</title>
            <description>PEG and RBV during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With cEVR12LOQ and cEVR12LOD (Genotype 2)</title>
          <population>Participants in the Full Analysis Set with genotype 2 HCV infection</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>cEVR12LOQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="96.7"/>
                    <measurement group_id="O3" value="80.8"/>
                    <measurement group_id="O4" value="100.0"/>
                    <measurement group_id="O5" value="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cEVR12LOD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="83.3"/>
                    <measurement group_id="O3" value="80.8"/>
                    <measurement group_id="O4" value="90.9"/>
                    <measurement group_id="O5" value="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With cEVR12LOQ and cEVR12LOD (Genotype 3)</title>
        <time_frame>after 12 weeks of treatment</time_frame>
        <population>Participants in the Full Analysis Set with genotype 3 HCV infection</population>
        <group_list>
          <group group_id="O1">
            <title>ALV 1000 mg</title>
            <description>ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.</description>
          </group>
          <group group_id="O2">
            <title>ALV 600 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O3">
            <title>ALV 800 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O4">
            <title>ALV 600 mg+PEG</title>
            <description>ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.</description>
          </group>
          <group group_id="O5">
            <title>PEG+RBV</title>
            <description>PEG and RBV during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With cEVR12LOQ and cEVR12LOD (Genotype 3)</title>
          <population>Participants in the Full Analysis Set with genotype 3 HCV infection</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>cEVR12LOQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4"/>
                    <measurement group_id="O2" value="94.4"/>
                    <measurement group_id="O3" value="94.0"/>
                    <measurement group_id="O4" value="92.9"/>
                    <measurement group_id="O5" value="85.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cEVR12LOD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.9"/>
                    <measurement group_id="O2" value="88.9"/>
                    <measurement group_id="O3" value="94.0"/>
                    <measurement group_id="O4" value="82.1"/>
                    <measurement group_id="O5" value="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With End of Treatment Response (ETR) Within 24 Weeks (ETR24LOQ and ETR24LOD)</title>
        <description>ETR24LOQ and ETR24LOD were defined as ETR [serum HCV RNA &lt; LOQ and &lt; LOD] after 24 weeks of treatment or when prematurely discontinued.</description>
        <time_frame>at end of treatment, within 24 weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>ALV 1000 mg</title>
            <description>ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.</description>
          </group>
          <group group_id="O2">
            <title>ALV 600 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O3">
            <title>ALV 800 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O4">
            <title>ALV 600 mg+PEG</title>
            <description>ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.</description>
          </group>
          <group group_id="O5">
            <title>PEG+RBV</title>
            <description>PEG and RBV during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With End of Treatment Response (ETR) Within 24 Weeks (ETR24LOQ and ETR24LOD)</title>
          <description>ETR24LOQ and ETR24LOD were defined as ETR [serum HCV RNA &lt; LOQ and &lt; LOD] after 24 weeks of treatment or when prematurely discontinued.</description>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ETR24LOQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.1"/>
                    <measurement group_id="O2" value="96.4"/>
                    <measurement group_id="O3" value="95.7"/>
                    <measurement group_id="O4" value="94.9"/>
                    <measurement group_id="O5" value="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ETR24LOD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.6"/>
                    <measurement group_id="O2" value="94.0"/>
                    <measurement group_id="O3" value="92.5"/>
                    <measurement group_id="O4" value="92.3"/>
                    <measurement group_id="O5" value="82.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ETR24LOQ and ETR24LOD (Genotype 2)</title>
        <time_frame>at end of treatment, within 24 weeks</time_frame>
        <population>Participants in the Full Analysis Set with genotype 2 HCV infection</population>
        <group_list>
          <group group_id="O1">
            <title>ALV 1000 mg</title>
            <description>ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.</description>
          </group>
          <group group_id="O2">
            <title>ALV 600 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O3">
            <title>ALV 800 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O4">
            <title>ALV 600 mg+PEG</title>
            <description>ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.</description>
          </group>
          <group group_id="O5">
            <title>PEG+RBV</title>
            <description>PEG and RBV during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ETR24LOQ and ETR24LOD (Genotype 2)</title>
          <population>Participants in the Full Analysis Set with genotype 2 HCV infection</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ETR24LOQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="96.7"/>
                    <measurement group_id="O3" value="84.6"/>
                    <measurement group_id="O4" value="100.0"/>
                    <measurement group_id="O5" value="92.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ETR24LOD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="96.7"/>
                    <measurement group_id="O3" value="76.9"/>
                    <measurement group_id="O4" value="100.0"/>
                    <measurement group_id="O5" value="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ETR24LOQ and ETR24LOD (Genotype 3)</title>
        <time_frame>at end of treatment, within 24 weeks</time_frame>
        <population>Participants in the Full Analysis Set with genotype 3 HCV infection</population>
        <group_list>
          <group group_id="O1">
            <title>ALV 1000 mg</title>
            <description>ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.</description>
          </group>
          <group group_id="O2">
            <title>ALV 600 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O3">
            <title>ALV 800 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O4">
            <title>ALV 600 mg+PEG</title>
            <description>ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.</description>
          </group>
          <group group_id="O5">
            <title>PEG+RBV</title>
            <description>PEG and RBV during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ETR24LOQ and ETR24LOD (Genotype 3)</title>
          <population>Participants in the Full Analysis Set with genotype 3 HCV infection</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ETR24LOQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.1"/>
                    <measurement group_id="O2" value="96.3"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="92.9"/>
                    <measurement group_id="O5" value="85.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ETR24LOD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.7"/>
                    <measurement group_id="O2" value="92.6"/>
                    <measurement group_id="O3" value="98.5"/>
                    <measurement group_id="O4" value="89.3"/>
                    <measurement group_id="O5" value="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With RVR Who Achieved Sustained Viral Response (SVR) 12 Weeks After the End of Treatment (SVR12LOQ and SVR12LOD)</title>
        <description>SVR12LOQ and SVR12LOD were defined as Sustained Viral Response (SVR) [serum HCV RNA &lt; LOQ and &lt; LOD] 12 weeks after treatment, respectively.</description>
        <time_frame>12 weeks after the end of treatment</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>ALV 1000 mg</title>
            <description>ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.</description>
          </group>
          <group group_id="O2">
            <title>ALV 600 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O3">
            <title>ALV 800 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O4">
            <title>ALV 600 mg+PEG</title>
            <description>ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.</description>
          </group>
          <group group_id="O5">
            <title>PEG+RBV</title>
            <description>PEG and RBV during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With RVR Who Achieved Sustained Viral Response (SVR) 12 Weeks After the End of Treatment (SVR12LOQ and SVR12LOD)</title>
          <description>SVR12LOQ and SVR12LOD were defined as Sustained Viral Response (SVR) [serum HCV RNA &lt; LOQ and &lt; LOD] 12 weeks after treatment, respectively.</description>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR12LOQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.5"/>
                    <measurement group_id="O2" value="84.5"/>
                    <measurement group_id="O3" value="80.6"/>
                    <measurement group_id="O4" value="76.9"/>
                    <measurement group_id="O5" value="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12LOD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.2"/>
                    <measurement group_id="O2" value="84.5"/>
                    <measurement group_id="O3" value="80.6"/>
                    <measurement group_id="O4" value="74.4"/>
                    <measurement group_id="O5" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With RVR Who Achieved SVR12LOQ and SVR12LOD (Genotype 2)</title>
        <time_frame>12 weeks after the end of treatment</time_frame>
        <population>Participants in the Full Analysis Set with genotype 2 HCV infection</population>
        <group_list>
          <group group_id="O1">
            <title>ALV 1000 mg</title>
            <description>ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.</description>
          </group>
          <group group_id="O2">
            <title>ALV 600 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O3">
            <title>ALV 800 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O4">
            <title>ALV 600 mg+PEG</title>
            <description>ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.</description>
          </group>
          <group group_id="O5">
            <title>PEG+RBV</title>
            <description>PEG and RBV during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With RVR Who Achieved SVR12LOQ and SVR12LOD (Genotype 2)</title>
          <population>Participants in the Full Analysis Set with genotype 2 HCV infection</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR12LOQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3"/>
                    <measurement group_id="O2" value="76.7"/>
                    <measurement group_id="O3" value="76.9"/>
                    <measurement group_id="O4" value="72.7"/>
                    <measurement group_id="O5" value="61.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12LOD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3"/>
                    <measurement group_id="O2" value="76.7"/>
                    <measurement group_id="O3" value="76.9"/>
                    <measurement group_id="O4" value="72.7"/>
                    <measurement group_id="O5" value="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With RVR Who Achieved SVR12LOQ and SVR12LOD (Genotype 3)</title>
        <time_frame>12 weeks after the end of treatment</time_frame>
        <population>Participants in the Full Analysis Set with genotype 3 HCV infection</population>
        <group_list>
          <group group_id="O1">
            <title>ALV 1000 mg</title>
            <description>ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.</description>
          </group>
          <group group_id="O2">
            <title>ALV 600 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O3">
            <title>ALV 800 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O4">
            <title>ALV 600 mg+PEG</title>
            <description>ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.</description>
          </group>
          <group group_id="O5">
            <title>PEG+RBV</title>
            <description>PEG and RBV during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With RVR Who Achieved SVR12LOQ and SVR12LOD (Genotype 3)</title>
          <population>Participants in the Full Analysis Set with genotype 3 HCV infection</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR12LOQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.8"/>
                    <measurement group_id="O2" value="88.9"/>
                    <measurement group_id="O3" value="82.1"/>
                    <measurement group_id="O4" value="78.6"/>
                    <measurement group_id="O5" value="63.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12LOD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0"/>
                    <measurement group_id="O2" value="88.9"/>
                    <measurement group_id="O3" value="82.1"/>
                    <measurement group_id="O4" value="75.0"/>
                    <measurement group_id="O5" value="63.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With RVR Who Achieved SVR at 24 Weeks After the End of Treatment (SVR24LOQ and SVR24LOD)</title>
        <time_frame>24 weeks after the end of treatment</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>ALV 1000 mg</title>
            <description>ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.</description>
          </group>
          <group group_id="O2">
            <title>ALV 600 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O3">
            <title>ALV 800 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O4">
            <title>ALV 600 mg+PEG</title>
            <description>ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.</description>
          </group>
          <group group_id="O5">
            <title>PEG+RBV</title>
            <description>PEG and RBV during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With RVR Who Achieved SVR at 24 Weeks After the End of Treatment (SVR24LOQ and SVR24LOD)</title>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR24LOQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.2"/>
                    <measurement group_id="O2" value="84.5"/>
                    <measurement group_id="O3" value="80.6"/>
                    <measurement group_id="O4" value="79.5"/>
                    <measurement group_id="O5" value="57.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR24LOD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.2"/>
                    <measurement group_id="O2" value="84.5"/>
                    <measurement group_id="O3" value="79.6"/>
                    <measurement group_id="O4" value="79.5"/>
                    <measurement group_id="O5" value="57.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With RVR Who Achieved SVR24LOQ and SVR24LOD (Genotype 2)</title>
        <time_frame>24 weeks after the end of treatment</time_frame>
        <population>Participants in the Full Analysis Set with genotype 2 HCV infection</population>
        <group_list>
          <group group_id="O1">
            <title>ALV 1000 mg</title>
            <description>ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.</description>
          </group>
          <group group_id="O2">
            <title>ALV 600 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O3">
            <title>ALV 800 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O4">
            <title>ALV 600 mg+PEG</title>
            <description>ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.</description>
          </group>
          <group group_id="O5">
            <title>PEG+RBV</title>
            <description>PEG and RBV during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With RVR Who Achieved SVR24LOQ and SVR24LOD (Genotype 2)</title>
          <population>Participants in the Full Analysis Set with genotype 2 HCV infection</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR24LOQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3"/>
                    <measurement group_id="O2" value="76.7"/>
                    <measurement group_id="O3" value="76.9"/>
                    <measurement group_id="O4" value="72.7"/>
                    <measurement group_id="O5" value="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR24LOD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3"/>
                    <measurement group_id="O2" value="76.7"/>
                    <measurement group_id="O3" value="76.9"/>
                    <measurement group_id="O4" value="72.7"/>
                    <measurement group_id="O5" value="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With RVR Who Achieved SVR24LOQ and SVR24LOD (Genotype 3)</title>
        <time_frame>24 weeks after the end of treatment</time_frame>
        <population>Participants in the Full Analysis Set with genotype 3 HCV infection</population>
        <group_list>
          <group group_id="O1">
            <title>ALV 1000 mg</title>
            <description>ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.</description>
          </group>
          <group group_id="O2">
            <title>ALV 600 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O3">
            <title>ALV 800 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O4">
            <title>ALV 600 mg+PEG</title>
            <description>ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.</description>
          </group>
          <group group_id="O5">
            <title>PEG+RBV</title>
            <description>PEG and RBV during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With RVR Who Achieved SVR24LOQ and SVR24LOD (Genotype 3)</title>
          <population>Participants in the Full Analysis Set with genotype 3 HCV infection</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR24LOQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0"/>
                    <measurement group_id="O2" value="88.9"/>
                    <measurement group_id="O3" value="82.1"/>
                    <measurement group_id="O4" value="82.1"/>
                    <measurement group_id="O5" value="59.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR24LOD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0"/>
                    <measurement group_id="O2" value="88.9"/>
                    <measurement group_id="O3" value="80.6"/>
                    <measurement group_id="O4" value="82.1"/>
                    <measurement group_id="O5" value="59.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With On-treatment Viral Breakthrough</title>
        <description>Viral breakthrough was defined as either:
Confirmed increase of HCV RNA ≥1 log10 above nadir (nadir = lowest HCV RNA value during treatment), or
HCV RNA becoming ≥ 100 IU/mL after previously being undetectable (&lt; LOD) during treatment</description>
        <time_frame>within 24 weeks of treatment</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>ALV 1000 mg</title>
            <description>ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.</description>
          </group>
          <group group_id="O2">
            <title>ALV 600 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O3">
            <title>ALV 800 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O4">
            <title>ALV 600 mg+PEG</title>
            <description>ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.</description>
          </group>
          <group group_id="O5">
            <title>PEG+RBV</title>
            <description>PEG and RBV during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With On-treatment Viral Breakthrough</title>
          <description>Viral breakthrough was defined as either:
Confirmed increase of HCV RNA ≥1 log10 above nadir (nadir = lowest HCV RNA value during treatment), or
HCV RNA becoming ≥ 100 IU/mL after previously being undetectable (&lt; LOD) during treatment</description>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="3.6"/>
                    <measurement group_id="O3" value="2.2"/>
                    <measurement group_id="O4" value="5.1"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Viral Relapse</title>
        <description>Viral relapse was defined as having reappearance of detectable HCV RNA after previously being undetectable (&lt; LOD) during treatment.</description>
        <time_frame>within 24 weeks after the end of treatment</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>ALV 1000 mg</title>
            <description>ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.</description>
          </group>
          <group group_id="O2">
            <title>ALV 600 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O3">
            <title>ALV 800 mg+RBV</title>
            <description>ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.</description>
          </group>
          <group group_id="O4">
            <title>ALV 600 mg+PEG</title>
            <description>ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.</description>
          </group>
          <group group_id="O5">
            <title>PEG+RBV</title>
            <description>PEG and RBV during Weeks 1 to 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Viral Relapse</title>
          <description>Viral relapse was defined as having reappearance of detectable HCV RNA after previously being undetectable (&lt; LOD) during treatment.</description>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 to 12 weeks after the end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9"/>
                    <measurement group_id="O2" value="8.3"/>
                    <measurement group_id="O3" value="6.5"/>
                    <measurement group_id="O4" value="10.3"/>
                    <measurement group_id="O5" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 to 24 weeks after the end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ALV 1000 mg: On-treatment AEs</title>
          <description>Adverse events (AEs) occurring while on treatment in participants receiving ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.</description>
        </group>
        <group group_id="E2">
          <title>ALV 600 mg+RBV: On-treatment AEs</title>
          <description>AEs occurring while on treatment in participants receiving ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.</description>
        </group>
        <group group_id="E3">
          <title>ALV 800 mg+RBV: On-treatment AEs</title>
          <description>AEs occurring while on treatment in participants receiving ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.</description>
        </group>
        <group group_id="E4">
          <title>ALV 600 mg+PEG: On-treatment AEs</title>
          <description>AEs occurring while on treatment in participants receiving ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.</description>
        </group>
        <group group_id="E5">
          <title>PEG+RBV: On-treatment AEs</title>
          <description>AEs occurring while on treatment in participants receiving PEG and RBV during Weeks 1 to 24.</description>
        </group>
        <group group_id="E6">
          <title>ALV 1000 mg: Post-treatment AEs</title>
          <description>AEs occurring after end of treatment in participants receiving ALV 600 mg BID for 1 week, followed by ALV 1000 mg QD during Weeks 2 to 24.</description>
        </group>
        <group group_id="E7">
          <title>ALV 600 mg+RBV: Post-treatment AEs</title>
          <description>AEs occurring after end of treatment in participants receiving ALV 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with RBV during Weeks 2 to 24.</description>
        </group>
        <group group_id="E8">
          <title>ALV 800 mg+RBV: Post-treatment AEs</title>
          <description>AEs occurring after end of treatment in participants receiving ALV 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.</description>
        </group>
        <group group_id="E9">
          <title>ALV 600 mg+PEG: Post-treatment AEs</title>
          <description>AEs occurring after end of treatment in participants receiving ALV 600 mg BID with PEG for 1 week, followed by ALV 600 mg QD with PEG during Weeks 2 to 24.</description>
        </group>
        <group group_id="E10">
          <title>PEG+RBV: Post-treatment AEs</title>
          <description>AEs occurring after end of treatment in participants receiving PEG and RBV during Weeks 1 to 24.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Muscle abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Tubo-ovarian abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Maternal exposure during pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Homicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema nodosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Motion sickness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal sensation in eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="94"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President Clinical Research &amp; Development</name_or_title>
      <organization>Debiopharm International S.A.</organization>
      <phone>4121 321 01 11</phone>
      <email>info-international@debiopharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

